Dual Antigen Targeting with Talquetamab plus Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - January 20, 2025 842 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the RedirecTT-1 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes the WHO Global Status Report on Cancer with Key Recommendations for Equitable Cancer Care Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive NSCLC GLP-1 Receptor Agonist Use Associated with a Significantly Lower Short-Term Incidence of Obesity-Associated Cancers Among Obese Individuals Without Diabetes MOST POPULAR Low Incidence of Local Recurrence When Omitting Radiotherapy after Breast-Conserving Surgery... August 22, 2023 Cancer “Decoys” Planted Underneath The Skin Lure In Cancer Cells And... November 4, 2019 5 questions the NHS Workforce Plan for England needs to answer June 27, 2023 6 of the biggest good news cancer stories of 2021 December 15, 2021 Load more HOT NEWS High Tumour Mutation Burden Fails to Predict Response to Immune Checkpoint... Empowering People With Cancer: A Q&A With Cancer.Net Editor in Chief... Inside Cancer Grand Challenges Part 1: what makes a grand challenge? Moving Beyond BMI: Low Muscle Mass May Affect Cancer Survival
